Support Our Work

About the Laboratory

The Dendritic Cell Research group (DCR) is directed by Associate Professor Georgina Clark. They discover key immune markers and biological processes which will provide new diagnostic and therapeutic products for improving patient care.

The group studies DC surface molecules to determine how these molecules influence DC function and how antibodies targeting them might be used in clinical practice. A major part of our work is aimed at using the patient’s immune responses to treat haematological cancers.

We are testing our findings in preclinical models of stem cell transplantation, leukaemia, multiple myeloma, prostate cancer and other malignancies.

more about us

About Our Team

Associate Professor Georgina Clark

A/Prof Clark set up Dendritic Cell Research (DCR) at the ANZAC Research Institute alongside the late Professor Derek Hart. Her interest lies in translational research developing antibodies to leucocyte surface molecules into immune therapies. The group’s translational pipeline from discovery of novel molecules (CD300 family, CD302, CD205, CD83, CMRF-56, CMRF-44) expressed by myeloid lineage cells including dendritic cells…..read more

Dr Xinsheng Ju

Dr Ju re-joined Professor Derek Hart, Dendritic Cell Research group in 2014 to continue his long term interests on DC biology and targeting CD83 molecule to control graft versus host disease (GVHD) and treat haematological malignancies…. read more

Meet the Whole Team

Our Research Specialities

Graft Versus Host Disease

Developing diagnostics and therapeutics for use in patients with graft versus host disease.

Dendritic cells (DC) are a special type of white blood cell that instruct the immune system. We have shown that changes in a specific type of DC can predict for the major complication in bone marrow transplantation …read more

Vaccine for AML

Therapeutic Vaccine for Acute Myeloid Leukaemia

Acute myeloid leukaemia (AML) affects around 900 Australians yearly, most commonly elderly patients. With current treatments, the overall survival rate is less than 10% for patients above 60 and at best 40% in younger individual…read more

Prostate Cancer Vaccine

Therapeutic Vaccine for Prostate Cancer

Prostate cancer is the most common cancer in Australian men and new therapies are needed. We can train the immune system to fight cancer by vaccinating patients using specialised white blood cells, called dendritic cells…read more

Transplant Outcomes

Specific Immuno- suppression to improve transplant outcomes

Current treatments for transplant patients suppress their whole immune system, making them susceptible to infections and cancer. We developed a therapeutic antibody that targets a molecule on a small population of active immune cells…read more

Current News

Immunology Company Kira Biotech launches with A$20M Series A Funding

Brisbane, 29 October 2019: Kira Biotech today announced it has secured Series A funding of A$20 million to develop therapeutics targeting difficult-to-treat immune system disorders.

The round was led by OneVentures, with significant investment from IP Group and support from the Advance Queensland Business Development Fund. The funds will help advance Kira Biotech’s lead candidate KB312 through phase 1 human studies. Read More

Dendritic Cell Research

The ANZAC Research Institute
Concord Repatriation General Hospital
Gate 3, Hospital Road
Concord NSW 2139, Australia

P: +61 2 9767 9100
F: +61 2 9767 9101
E: dcr.admin@sydney.edu.au

Subscribe to our Newsletter

Subscribe to our e-newsletter and receive quarterly updates about our people, research projects, achievements and how you can help.

SUBSCRIBE HERE